In 2002, Avant Immunotherapeutics (until 2008 NASDAQ: AVAN) working on vaccines against viral and bacterial diseases and itself having extensive involvement with SBIR, licensed exclusive rights to Universal Preservation Technologies' intellectual property and patented VitriLife technology to use with its (Avant's) oral vaccines and certain other non-injectables. niversal Stabilization Technologies, Inc. ("UST") shifted focus to preserving biological materials, The firm is organized around developing novel long-term stabilization (preservation) technologies that enable the formulation, development, and delivery of ambient temperature stable vaccines and other biologics with higher yields and at higher temperatures than currently possible. UST's mission, corporate objective, and core competency is to develop vaccines and other biologics that have higher long-term stability at ambient temperatures and environments, cost less to manufacture, and eliminate the need to maintain costly temperature-control systems (i.e. "cold chain") for long-term storage, transport, and distribution.
